CO2020013561A2 - Nueva sal de cisteamina para la preparación de partículas altamente inhalables - Google Patents

Nueva sal de cisteamina para la preparación de partículas altamente inhalables

Info

Publication number
CO2020013561A2
CO2020013561A2 CONC2020/0013561A CO2020013561A CO2020013561A2 CO 2020013561 A2 CO2020013561 A2 CO 2020013561A2 CO 2020013561 A CO2020013561 A CO 2020013561A CO 2020013561 A2 CO2020013561 A2 CO 2020013561A2
Authority
CO
Colombia
Prior art keywords
preparation
new
inhalable particles
cysteamine salt
highly
Prior art date
Application number
CONC2020/0013561A
Other languages
English (en)
Inventor
Marco Barchielli
Paolo Colombo
Alessandra Rossi
Greta Adorni
Original Assignee
Recordati Ind Chimica E Farmaceutica Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica Spa filed Critical Recordati Ind Chimica E Farmaceutica Spa
Publication of CO2020013561A2 publication Critical patent/CO2020013561A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención proporciona micropartículas inhalables que comprenden sal de hialuronato de cisteamina. También se proporcionan un método de preparación y una composición farmacéutica de la misma.
CONC2020/0013561A 2018-05-22 2020-11-18 Nueva sal de cisteamina para la preparación de partículas altamente inhalables CO2020013561A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18425038.9A EP3572068A1 (en) 2018-05-22 2018-05-22 New salt of cysteamine for the preparation of highly respirable particles
PCT/EP2019/062872 WO2019224130A1 (en) 2018-05-22 2019-05-17 New salt of cysteamine for the preparation of highly respirable particles

Publications (1)

Publication Number Publication Date
CO2020013561A2 true CO2020013561A2 (es) 2020-12-10

Family

ID=62750913

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013561A CO2020013561A2 (es) 2018-05-22 2020-11-18 Nueva sal de cisteamina para la preparación de partículas altamente inhalables

Country Status (20)

Country Link
US (1) US11602509B2 (es)
EP (2) EP3572068A1 (es)
JP (1) JP7281485B2 (es)
KR (2) KR20200138782A (es)
CN (1) CN112020348B (es)
AU (1) AU2019273612A1 (es)
BR (1) BR112020023812A2 (es)
CA (1) CA3094909A1 (es)
CO (1) CO2020013561A2 (es)
DK (1) DK3796888T3 (es)
EA (1) EA202092751A1 (es)
ES (1) ES2908829T3 (es)
HU (1) HUE058805T2 (es)
IL (1) IL277933B2 (es)
LT (1) LT3796888T (es)
MX (1) MX2020012471A (es)
PL (1) PL3796888T3 (es)
PT (1) PT3796888T (es)
UA (1) UA126705C2 (es)
WO (1) WO2019224130A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6312293A (ja) * 1986-07-03 1988-01-19 Kyowa Hakko Kogyo Co Ltd ヒアルロン酸の精製法
IT1271001B (it) * 1994-07-26 1997-05-26 Poli Ind Chimica Spa Procedimento di preparazione di acido ialuronico mediante fermentazione con streptococcus
JP3888753B2 (ja) * 1997-12-05 2007-03-07 帝人株式会社 持続性粉末状吸入用医薬品組成物
WO2009036906A1 (de) 2007-09-22 2009-03-26 Bayer Consumer Care Ag Zusammensetzung mit wirkstoffkombination aus einem laxans und einem entschäumer zur behandlung von obstipation
CN101367884A (zh) 2008-09-25 2009-02-18 复旦大学 一种半胱胺修饰的巯基化透明质酸偶合物及其制备方法和应用
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
AR110125A1 (es) * 2016-11-07 2019-02-27 Croma Pharma Ges M B H Compuestos poliméricos que liberan sulfuro de hidrógeno

Also Published As

Publication number Publication date
CN112020348B (zh) 2024-04-12
IL277933B2 (en) 2024-02-01
HUE058805T2 (hu) 2022-09-28
KR20230051306A (ko) 2023-04-17
MX2020012471A (es) 2021-02-09
JP7281485B2 (ja) 2023-05-25
EP3572068A1 (en) 2019-11-27
KR20200138782A (ko) 2020-12-10
IL277933A (en) 2020-11-30
WO2019224130A1 (en) 2019-11-28
CA3094909A1 (en) 2019-11-28
LT3796888T (lt) 2022-04-11
BR112020023812A2 (pt) 2021-02-23
UA126705C2 (uk) 2023-01-11
US11602509B2 (en) 2023-03-14
EP3796888B1 (en) 2022-02-16
JP2021523893A (ja) 2021-09-09
KR102640737B1 (ko) 2024-02-23
US20210236439A1 (en) 2021-08-05
PT3796888T (pt) 2022-03-11
IL277933B1 (en) 2023-10-01
AU2019273612A1 (en) 2020-10-15
DK3796888T3 (da) 2022-03-14
PL3796888T3 (pl) 2022-05-09
CN112020348A (zh) 2020-12-01
EA202092751A1 (ru) 2021-03-12
EP3796888A1 (en) 2021-03-31
ES2908829T3 (es) 2022-05-04

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
EP3630145A4 (en) PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM
BR112018003984A2 (pt) anticorpos
EP3471778A4 (en) COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112016022345A2 (pt) terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
PL3805198T3 (pl) Związek, jego sól i cząstki lipidowe
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
IL279879A (en) Antibodies against disease-causing substances in poultry and their uses
CO2020016582A2 (es) Sales de sepiapterina farmacéuticamente aceptables
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112022008365A2 (pt) Inibidores de cd73
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων